Panther Biotechnology acquires Alchemia Oncology Pty Limited and with it HA-Irinotecan

Panther Biotechnology, Inc. a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, announced that it has entered into an agreement to acquire Alchemia Oncology Pty Limited, a wholly owned subsidiary of Alchemia Limited, an Australian biotechnology company listed on the Australian Stock Exchange (ACL). Alchemia Oncology Pty Limited has a robust collection of clinical and pre-clinical oncology assets, which include the HyACT Drug Delivery Platform, a portfolio of targeted therapeutics which are designed to exploit the unique structure and inherent biological properties of Hyaluronic Acid. Drug candidates in the portfolio range from pre-clinical through phase III. Panther intends to file a new phase III protocol against an open IND with the FDA for HA-Irinotecan in 2015, in addition to advancing the other phase II and phase 1b clinical drug candidates.